Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Cerimon Pharmaceuticals has entered into an agreement with Novartis Pharma to conduct a proof of concept study for Simulect or basiliximab for the treatment of noninfectious uveitis, an autoimmune inflammation of the eye's internal structures.
Subscribe to our email newsletter
Basiliximab is a monoclonal antibody that selectively blocks the interleukin-2 receptor. This mechanism of action provides highly targeted inhibition of the T-lymphocyte activation that is involved in serious immune-related diseases.
Daniel Levitt, executive vice president of R&D at Cerimon, said: “Basiliximab has the potential to significantly improve the quality of life for this group of uveitis patients and reduce adverse events often associated with current treatments that include corticosteroids and other immunosuppressive therapies.”